Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Qi Niu

Showing results (181-190 of 194) with videos related to

Pageof 20
Sort By:
Nature Communications|April 5, 2019
NKG2A is a NK cell exhaustion checkpoint for HCV persistenceChao Zhang, Xiao-Mei Wang, Shu-Ran Li, et al.
NAR Genomics and Bioinformatics|August 8, 2022
Mining bacterial NGS data vastly expands the complete genomes of temperate phagesXianglilan Zhang, Ruohan Wang, Xiangcheng Xie, et al.
JAMA Network Open|February 24, 2025
Tetramethylpyrazine Nitrone in Amyotrophic Lateral Sclerosis: A Randomized Clinical TrialXiaolu Liu, Huifang Shang, Qianqian Wei, et al.
Journal of Digestive Diseases|February 2, 2018
Tolvaptan in Chinese cirrhotic patients with ascites: A randomized, placebo-controlled phase 2 trialYong Feng Wang, Jie Ting Tang, Tao Han, et al.
Hepatology International|July 24, 2015
Two-year results of a randomized, phase III comparative trial of telbivudine versus lamivudine in Chinese patientsJi-Dong Jia, Jin-Lin Hou, You-Kuan Yin, et al.
Plos One|July 4, 2008
A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patientsDao-Zhen Xu, Kai Zhao, Li-Min Guo, et al.
Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology|May 26, 2007
[The degree of HBV suppression with 24 week telbivudine- or lamivudine-treatment in hepatitis B patients predicts the efficacy of the treatment at week 52]Ji-dong Jia, Jin-lin Hou, You-kuan Yin, et al.
World Journal of Gastroenterology|March 31, 2018
Daclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infectionLai Wei, Fu-Sheng Wang, Ming-Xiang Zhang, et al.
Journal of Gastroenterology and Hepatology|October 13, 2018
Efficacy and safety of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1, 4, or 6 infection from the Asia-Pacific region and Russia: Final results from the randomized C-CORAL studyLai Wei, Ji Dong Jia, Fu Sheng Wang, et al.
Journal of Digestive Diseases|July 24, 2020
Multicenter prospective study to validate a new transient elastography device for staging liver fibrosis in patients with chronic hepatitis BWei Jia Duan, Xiao Zhong Wang, An Lin Ma, et al.
Pageof 20

Showing results (181-190 of 194) with videos related to

Sort By:
Pageof 20
Nature Communications|April 5, 2019
NKG2A is a NK cell exhaustion checkpoint for HCV persistenceChao Zhang, Xiao-Mei Wang, Shu-Ran Li, et al.
NAR Genomics and Bioinformatics|August 8, 2022
Mining bacterial NGS data vastly expands the complete genomes of temperate phagesXianglilan Zhang, Ruohan Wang, Xiangcheng Xie, et al.
JAMA Network Open|February 24, 2025
Tetramethylpyrazine Nitrone in Amyotrophic Lateral Sclerosis: A Randomized Clinical TrialXiaolu Liu, Huifang Shang, Qianqian Wei, et al.
Journal of Digestive Diseases|February 2, 2018
Tolvaptan in Chinese cirrhotic patients with ascites: A randomized, placebo-controlled phase 2 trialYong Feng Wang, Jie Ting Tang, Tao Han, et al.
Hepatology International|July 24, 2015
Two-year results of a randomized, phase III comparative trial of telbivudine versus lamivudine in Chinese patientsJi-Dong Jia, Jin-Lin Hou, You-Kuan Yin, et al.
Plos One|July 4, 2008
A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patientsDao-Zhen Xu, Kai Zhao, Li-Min Guo, et al.
Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology|May 26, 2007
[The degree of HBV suppression with 24 week telbivudine- or lamivudine-treatment in hepatitis B patients predicts the efficacy of the treatment at week 52]Ji-dong Jia, Jin-lin Hou, You-kuan Yin, et al.
World Journal of Gastroenterology|March 31, 2018
Daclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infectionLai Wei, Fu-Sheng Wang, Ming-Xiang Zhang, et al.
Journal of Gastroenterology and Hepatology|October 13, 2018
Efficacy and safety of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1, 4, or 6 infection from the Asia-Pacific region and Russia: Final results from the randomized C-CORAL studyLai Wei, Ji Dong Jia, Fu Sheng Wang, et al.
Journal of Digestive Diseases|July 24, 2020
Multicenter prospective study to validate a new transient elastography device for staging liver fibrosis in patients with chronic hepatitis BWei Jia Duan, Xiao Zhong Wang, An Lin Ma, et al.
Pageof 20